Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter Phase 3 Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) to Compare the Efficacy, Safety and Immunogenicity of PB016 and Entyvio® for the Induction and Maintenance of Clinical Response and Remission

NCT05771155 is registered in ClinicalTrials.gov with Polpharma Biologics S.A. as lead sponsor.

NCT NCT05771155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05771155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter Phase 3 Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) to Compare the Efficacy, Safety and Immunogenicity of PB016 and Entyvio® for the Induction and Maintenance of Clinical Response and Remission
Lead sponsor
Polpharma Biologics S.A.
Phase
Phase 3
Overall status
Unknown status
Start date
July 24, 2023
Completion date
September 30, 2025
Enrollment
750 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis